Cargando…

Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

Detalles Bibliográficos
Autores principales:	Ha, Ji-Hee, Kim, Jung-Eun, Kim, Yong-Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694218/ https://www.ncbi.nlm.nih.gov/pubmed/29151837 http://dx.doi.org/10.3389/fimmu.2017.01582

Ejemplares similares

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
por: Ha, Ji-Hee, et al.
Publicado: (2016)

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies
por: Skegro, Darko, et al.
Publicado: (2017)

Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening
por: Choi, Hye-Ji, et al.
Publicado: (2015)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
por: Lei, Cheng, et al.
Publicado: (2018)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
por: Mimura, Yusuke, et al.
Publicado: (2022)

Corrigendum: Inside-Out Control of Fc-Receptors
por: Koenderman, Leo
Publicado: (2019)

Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions
por: Lopez, Ester, et al.
Publicado: (2019)

Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Publicado: (2022)

Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
por: Elter, Adrian, et al.
Publicado: (2021)

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
por: Bohländer, Fabian, et al.
Publicado: (2021)

Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation
por: Yang, SeungCheon, et al.
Publicado: (2021)

Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation
por: Hong, Jung Yeon, et al.
Publicado: (2016)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2023)

Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
por: Sand, Kine Marita Knudsen, et al.
Publicado: (2015)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa(V158) Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
por: Kang, Tae Hyun, et al.
Publicado: (2019)

A general Fc engineering platform for the next generation of antibody therapeutics
por: Chen, Da, et al.
Publicado: (2021)

Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors
por: Syenina, Ayesa, et al.
Publicado: (2015)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2018)

Corrigendum: Development of a Scrub Typhus Diagnostic Platform Incorporating Cell-Surface Display Technology
por: Liao, Chih-Chi, et al.
Publicado: (2021)

Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
por: Yang, Chunpeng, et al.
Publicado: (2018)

Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans
por: Kendrick, Felicity, et al.
Publicado: (2019)

The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease
por: Chang, Ling-Sai, et al.
Publicado: (2016)

Corrigendum: The Role Played by Mitochondria in FcϵRI-Dependent Mast Cell Activation
por: Chelombitko, Maria A., et al.
Publicado: (2020)

Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain
por: Johnson, Derrick, et al.
Publicado: (2021)

Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models
por: Schmaljohn, Alan L., et al.
Publicado: (2019)

Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses
por: Orange, Jordan S., et al.
Publicado: (2015)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity
por: Peschke, Benjamin, et al.
Publicado: (2017)

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
por: Dekkers, Gillian, et al.
Publicado: (2017)

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc
por: Dadas, Osman, et al.
Publicado: (2023)

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
por: Cox, Freek, et al.
Publicado: (2016)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes
por: Lippold, Steffen, et al.
Publicado: (2023)

Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications
por: Rath, Timo, et al.
Publicado: (2015)

IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
por: Breedveld, Annelot, et al.
Publicado: (2019)

The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019)

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019)

Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
por: Su, Bin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2lhgkpna0hjvigfj20livt51gv